Vitamin E: Benefits, Forms, Dosing, and Side Effects

Vitamin E is not a single molecule but a family of eight fat-soluble compounds with antioxidant activity: four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta) [1][2]. Of these eight forms, only alpha-tocopherol is recognized to meet human nutritional requirements, and the Recommended Dietary Allowance (RDA) is defined exclusively for alpha-tocopherol [1][2].

The biological preference for alpha-tocopherol is determined by the liver. After absorption from the small intestine, the hepatic alpha-tocopherol transfer protein selectively resecretes alpha-tocopherol into the bloodstream while metabolizing and excreting other vitamin E forms [2][3]. As a result, blood and cellular concentrations of alpha-tocopherol are substantially higher than those of other forms, and alpha-tocopherol has been the subject of the vast majority of clinical research [2][4].

Vitamin E functions primarily as a chain-breaking antioxidant that halts the propagation of lipid peroxidation in cell membranes and lipoproteins [1][2]. Beyond its antioxidant role, vitamin E is involved in immune function, cell signaling, regulation of gene expression, and inhibition of platelet aggregation [1][2]. Alpha-tocopherol inhibits protein kinase C (involved in smooth muscle cell proliferation), enhances prostacyclin release from endothelial cells (promoting vasodilation and inhibiting platelet aggregation), and supports immune cell function [1][2].

Frank vitamin E deficiency is rare in the United States — less than 1% of adults are deficient [5]. The RDA of 15 mg/day for adults is easily achievable through dietary sources such as nuts, seeds, and vegetable oils [1][2]. Despite its essential role, large randomized controlled trials have consistently failed to demonstrate benefits for cardiovascular disease or cancer prevention in well-nourished populations, and several have identified potential harms — most notably a 17% increased risk of prostate cancer in the SELECT trial [7][8]. The US Preventive Services Task Force concluded in 2022 that there is no net benefit of vitamin E supplementation for the prevention of cardiovascular disease or cancer [8].

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Vitamin E is the collective name for a group of fat-soluble compounds with distinctive antioxidant activities. Naturally occurring vitamin E exists in eight chemical forms (alpha-, beta-, gamma-, and delta-tocopherol and alpha-, beta-, gamma-, and delta-tocotrienol) that have varying levels of biological activity [1][2]. Alpha-tocopherol is the only form recognized to meet human requirements.

Serum concentrations of vitamin E (alpha-tocopherol) depend on the liver, which takes up the nutrient after the various forms are absorbed from the small intestine. The liver preferentially resecretes only alpha-tocopherol via the hepatic alpha-tocopherol transfer protein; it metabolizes and excretes the other vitamin E forms [2][3]. As a result, blood and cellular concentrations of other forms of vitamin E are lower than those of alpha-tocopherol.

Vitamin E is a fat-soluble antioxidant that stops the production of reactive oxygen species (ROS) formed when fat undergoes oxidation. In addition to its activities as an antioxidant, vitamin E is involved in immune function, cell signaling, regulation of gene expression, and other metabolic processes [1][2]. Alpha-tocopherol inhibits the activity of protein kinase C, an enzyme involved in cell proliferation and differentiation in smooth muscle cells, platelets, and monocytes. Vitamin E also increases the expression of two enzymes that suppress arachidonic acid metabolism, thereby increasing the release of prostacyclin from the endothelium, which dilates blood vessels and inhibits platelet aggregation [2].

Serious vitamin E deficiency is rare — less than 1% of US adults are deficient [5]. True deficiency occurs primarily in people with fat-malabsorption disorders (Crohn's disease, cystic fibrosis, inability to secrete bile), rare inherited conditions such as abetalipoproteinemia and AVED (ataxia with vitamin E deficiency), and very low birth weight premature infants [1][2]. Deficiency symptoms include peripheral neuropathy, ataxia, skeletal myopathy, retinopathy, and impaired immune response [1][2].

A study funded by a vitamin E manufacturer (DSM Nutritional Products) claimed 87% of younger Americans had "inadequate" vitamin E levels, but it used a threshold of 30 micromol/L — well above the clinical deficiency cutoff of 12 micromol/L — and this claim has been criticized as misleading [5]. Current recommended intakes can be easily obtained from foods such as seeds, nuts, oils, and fruits.

Forms and Bioavailability

Natural vs. Synthetic Alpha-Tocopherol

The distinction between natural and synthetic vitamin E is clinically important because it affects both potency and safety.

Natural vitamin E (d-alpha-tocopherol, also called RRR-alpha-tocopherol) exists in a single stereoisomeric form that is fully biologically active. It may be stabilized as d-alpha-tocopheryl acetate or d-alpha-tocopheryl succinate without loss of bioavailability — the body hydrolyzes these esters efficiently [1][2]. Natural vitamin E products also contain varying amounts of other tocopherols (beta, gamma, delta) and tocotrienols.

Synthetic vitamin E (dl-alpha-tocopherol, also called all-rac-alpha-tocopherol) contains equal amounts of eight stereoisomers, but only four of these are maintained by the body [1][2]. Consequently, a given weight of synthetic alpha-tocopherol provides only half the biological activity of the same weight of natural alpha-tocopherol. Synthetic vitamin E does not contain any additional tocopherols or tocotrienols [5].

IU to Milligram Conversions

Since January 2020, the FDA requires vitamin E to be labeled in milligrams rather than International Units (IU), though products may include both [2][9]. The conversion factors differ between natural and synthetic forms:

Conversion	Natural (d-alpha)	Synthetic (dl-alpha)
1 IU equals	0.67 mg alpha-tocopherol	0.45 mg alpha-tocopherol
1 mg alpha-tocopherol equals	1.49 IU	2.22 IU
15 mg (the RDA) equals	22.4 IU	33.3 IU

These conversions matter for both efficacy and safety. For example, a supplement labeled "400 IU natural vitamin E" provides 268 mg of alpha-tocopherol, while "400 IU synthetic vitamin E" provides only 180 mg — a 33% difference in active compound [2].

Identifying Natural vs. Synthetic on Labels

Natural vitamin E is identified by the prefix "d-" (e.g., d-alpha-tocopherol, d-alpha-tocopheryl acetate). Synthetic vitamin E uses "dl-" (e.g., dl-alpha-tocopherol). Acceptable variations include "tocopheryl" instead of "tocopherol" and suffixes like "acetate," "succinate," or "acid succinate" [5]. Products labeled as "mixed tocopherols" typically contain a blend of natural alpha-, beta-, gamma-, and delta-tocopherol.

Mixed Tocopherols

Natural sources of vitamin E contain multiple tocopherol forms. Oils from corn, soybean, sesame, and cottonseed, as well as nuts, contain three to five times more gamma-tocopherol than alpha-tocopherol [5]. Some manufacturers market "mixed tocopherol" products on the premise that these additional forms provide complementary benefits.

However, the evidence for gamma-tocopherol is mixed. Some animal research suggests that natural vitamin E rich in gamma-tocopherol and delta-tocopherol may have cancer-preventive properties superior to alpha-tocopherol alone [10]. But observational data from 5,768 adults in NHANES found that higher blood levels of gamma-tocopherol were associated with shortened telomere length — a marker linked to aging and cancer risk — while higher alpha-tocopherol levels showed no such association [11]. Additionally, supplementation with high-dose alpha-tocopherol alone may decrease body levels of gamma- and delta-tocopherol, with uncertain health implications [5].

Tocotrienols

Tocotrienols (alpha, beta, gamma, delta) are structurally related to tocopherols but have an unsaturated side chain. They are particularly abundant in palm fruit oil, rice bran oil, barley, and wheat germ [5][2]. Although preliminary studies suggested potential for tocotrienols in reducing cholesterol levels and preventing heart disease, later studies have failed to confirm these benefits [12].

The most promising area for tocotrienols appears to be hair health. A study in Malaysia among 35 adults (age 18-59) with hair loss found that 50 mg of mixed tocotrienols (30.8% alpha, 56.4% gamma, 12.8% delta) daily for 8 months increased hair count in a 4 cm² area by approximately 35% compared to a 0.1% decrease in the placebo group [13].

Water-Soluble Forms

People with fat-malabsorption disorders (Crohn's disease, cystic fibrosis, cholestatic liver disease) may require water-soluble vitamin E, such as tocopheryl polyethylene glycol-1000 succinate (TPGS), to achieve adequate absorption [1][2]. Individuals with abetalipoproteinemia require very large doses (approximately 100 mg/kg/day, or 5-10 g/day) of supplemental vitamin E to prevent neurological damage [1][2].

Evidence for Benefits

Alzheimer's Disease and Cognitive Decline

High-dose vitamin E supplementation has shown modest benefit in people with existing Alzheimer's disease, but it does not appear to prevent cognitive decline in healthy individuals.

Mild to moderate Alzheimer's disease: A study of 613 veterans with mild to moderate Alzheimer's disease already taking acetylcholinesterase inhibitors found that 2,000 IU/day of synthetic vitamin E (dl-alpha-tocopherol acetate, given as 1,000 IU twice daily) preserved the ability to perform activities of daily living for approximately six months longer than placebo, reducing caregiver time. This benefit was not found for memantine alone or vitamin E plus memantine. Memory and cognition appeared to decline less with vitamin E, but the difference was not statistically significant. No significant differences in adverse events or mortality were observed (Dysken, JAMA 2014) [14].

Earlier trials in Alzheimer's: A controlled trial in 341 patients with moderately severe Alzheimer's disease found that 2,000 IU/day of dl-alpha-tocopherol significantly delayed functional deterioration and institutionalization compared to placebo, though participants taking vitamin E experienced significantly more falls (Sano, N Engl J Med 1997) [15].

Mild cognitive impairment: A trial of 769 individuals with mild cognitive impairment found that 2,000 IU/day of vitamin E did not significantly slow conversion to Alzheimer's disease compared to placebo (Petersen, N Engl J Med 2005) [16].

Healthy older men — no benefit: Among older men with normal cognitive function, 400 IU/day of synthetic vitamin E with or without high-dose selenium did not significantly reduce the risk of developing dementia over 6 years (Kryscio, JAMA Neurol 2017) [17].

Healthy older women — no benefit: A clinical trial in primarily healthy older women randomly assigned to receive 600 IU of natural vitamin E every other day or placebo for up to 4 years found no apparent cognitive benefits (Kang, Arch Intern Med 2006) [18].

Observational data: Vitamin E consumption from foods or supplements was associated with less cognitive decline over 3 years in a prospective cohort study of free-living individuals aged 65-102, suggesting dietary vitamin E intake may have a role that supplements at high doses do not replicate (Morris, Arch Neurol 2002) [19].

Synthesis: Vitamin E at 2,000 IU/day may modestly slow functional decline in patients with established Alzheimer's disease, but it does not appear to prevent cognitive decline or dementia in healthy or mildly impaired individuals [1][17][18][20].

Cardiovascular Disease

Vitamin E was once considered promising for cardiovascular disease (CVD) prevention based on strong observational evidence, but randomized clinical trials have consistently failed to demonstrate benefit, and some suggest harm.

Observational studies (positive): A study of approximately 90,000 nurses found that those with the highest vitamin E intakes (primarily from supplements) had 30-40% lower incidence of heart disease (Stampfer, N Engl J Med 1993) [21]. Among 5,133 Finnish men and women followed for 14 years, higher dietary vitamin E intakes were associated with decreased coronary heart disease mortality (Knekt, Am J Epidemiol 1994) [22].

HOPE and HOPE-TOO trials (no benefit, possible harm): The Heart Outcomes Prevention Evaluation study followed almost 10,000 patients at high cardiovascular risk for 4.5 years. Participants taking 400 IU/day of natural vitamin E (268 mg) experienced no fewer cardiovascular events than placebo [23]. In the HOPE-TOO extension (7 total years), vitamin E provided no protection against heart attacks, strokes, unstable angina, or cardiovascular death. However, participants on vitamin E were 13% more likely to experience and 21% more likely to be hospitalized for heart failure (Lonn, JAMA 2005) [24].

Women's Angiographic Vitamin and Estrogen Study (harm): Among 423 postmenopausal women with coronary stenosis, supplementation with 400 IU vitamin E plus 500 mg vitamin C twice daily for over 4 years showed no cardiovascular benefit, and all-cause mortality was significantly higher in the supplement group (Waters, JAMA 2002) [25].

Women's Health Study (mixed): Among nearly 40,000 healthy women aged 45 and older randomly assigned to 600 IU natural vitamin E every other day or placebo for 10 years, there were no significant differences in overall cardiovascular events. However, women taking vitamin E had a 24% reduction in cardiovascular death, and those aged 65 and older had a 26% decrease in nonfatal heart attack and a 49% decrease in cardiovascular death (Lee, JAMA 2005) [26].

Physicians' Health Study II (no benefit): Among nearly 15,000 healthy male physicians aged 50 and older randomly assigned to 400 IU synthetic vitamin E every other day for 8 years, vitamin E had no effect on major cardiovascular events, myocardial infarction, stroke, or cardiovascular mortality. Use of vitamin E was associated with a significantly increased risk of hemorrhagic stroke (Sesso, JAMA 2008) [27].

Stroke risk: A review of clinical studies found that vitamin E supplementation may reduce the risk of ischemic stroke by 10% but raise the risk of hemorrhagic stroke by 22%, leading researchers to conclude that "indiscriminate widespread use of vitamin E should be cautioned against" (Schurks, BMJ 2010) [28].

Interaction with cholesterol drugs: A combination of antioxidants including vitamin E blunted the rise in HDL cholesterol (especially the cardioprotective HDL2 fraction) in patients treated with simvastatin and niacin (Brown, N Engl J Med 2001; Cheung, Arterioscler Thromb Vasc Biol 2001) [29][30].

USPSTF conclusion: The US Preventive Services Task Force concluded in 2022 that there is no net benefit of vitamin E supplementation for the prevention of cardiovascular disease (USPSTF, JAMA 2022) [8].

Cancer

Despite initial promise from observational studies, clinical trials have not demonstrated that vitamin E supplementation prevents cancer. For prostate cancer, the evidence points toward increased risk.

Prostate cancer — SELECT trial: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) enrolled 35,533 healthy men aged 50 and older. After approximately 5.5 years, vitamin E supplementation (400 IU/day synthetic) was stopped due to lack of benefit. After a total of approximately 7 years of follow-up, men who had taken vitamin E had a 17% increased risk of prostate cancer compared to placebo, a statistically significant finding (Klein, JAMA 2011) [7]. Further analysis revealed this effect did not occur in men with already-high selenium levels; however, among men low in selenium, vitamin E increased the risks of low-grade and high-grade prostate cancer by 46% and 111%, respectively. High-dose selenium (200 mcg/day) increased high-grade prostate cancer risk by 91% among men with already-high selenium levels. The researchers cautioned that men aged 55 and older should avoid supplementation with either vitamin E or selenium at doses exceeding recommended daily intakes (Kristal, JNCI 2014) [31].

ATBC study in smokers: A study in 29,133 long-term male smokers found that supplementation with 50 IU/day (50 mg) of synthetic vitamin E for 5-8 years produced no reduction in lung cancer risk but did show a 32-35% reduction in prostate cancer risk (ATBC, N Engl J Med 1994; Heinonen, JNCI 1998) [32][33]. This paradoxical finding partly motivated the larger SELECT trial, which ultimately demonstrated harm at higher doses.

HOPE-TOO (no benefit): No significant differences in new cancer diagnoses or cancer deaths were found between vitamin E (400 IU/day natural) and placebo groups after 7 years (Lonn, JAMA 2005) [24].

Women's Health Study (no benefit): Among nearly 40,000 healthy women, 600 IU natural vitamin E every other day for 10 years did not reduce the risk of any form of cancer (Lee, JAMA 2005) [26].

Colon cancer — mixed: A study of women in Iowa found that the highest quintile of vitamin E intake (>35.7 IU/day) had 68% lower colon cancer risk compared to the lowest quintile, especially in women under 65 (Bostick, Cancer Res 1993) [34]. However, prospective cohort studies of 87,998 women (Nurses' Health Study) and 47,344 men (Health Professionals Follow-up Study) failed to replicate this finding (Wu, Cancer Epidemiol Biomarkers Prev 2002) [35].

Bladder cancer: An epidemiological study of almost one million adults by the American Cancer Society found that adults who took supplemental vitamin E for 10 years or longer had a reduced risk of death from bladder cancer (Jacobs, Am J Epidemiol 2002) [36].

Liver cancer (dietary intake): A study following over 100,000 people in China for up to 11 years found that higher dietary vitamin E intake and supplement use were associated with significantly lower liver cancer risk (Zhang, JNCI 2012) [37]. However, the majority of participants were consuming far below the RDA, making this finding unlikely to generalize to well-nourished Western populations.

Chemotherapy-induced neuropathy: Taking 300-600 mg of vitamin E daily during chemotherapy does not appear to prevent chemotherapy-induced peripheral neuropathy (Huang, Contemp Oncol 2016) [38]. The American Society of Clinical Oncology recommends against offering vitamin E for preventing chemotherapy-related nerve damage (Loprinzi, J Clin Oncol 2020) [39].

USPSTF conclusion: There is no net benefit of vitamin E supplementation for cancer prevention in healthy adults (USPSTF, JAMA 2022) [8].

Eye Diseases

Age-related macular degeneration (AMD): Prospective cohort studies found that people with relatively high dietary vitamin E intakes (approximately 20 mg/day) had about 20% lower risk of AMD compared to those with low intakes [2][40]. However, two RCTs using supplemental vitamin E alone failed to show protection [41][42].

The Age-Related Eye Disease Study (AREDS), a landmark RCT, found that a combination supplement containing vitamin E (400 IU synthetic), beta-carotene, vitamin C (500 mg), zinc (80 mg), and copper (2 mg) reduced the risk of developing advanced AMD by 25% over 5 years in people already at high risk [43]. The AREDS2 follow-up confirmed these results [44]. Notably, this benefit was from a specific combination formula, not vitamin E alone.

Cataracts: A large US study in healthy male physicians aged 50 and older found that 8 years of supplementation with vitamin E (400 IU every other day, synthetic) and/or vitamin C (500 mg/day) produced no significant reduction in cataract risk (Christen, Arch Ophthalmol 2010) [45]. A separate large study found that approximately 5 years of vitamin E (400 IU/day synthetic) and/or selenium (200 mcg/day) had no beneficial effect on age-related cataract (Christen, JAMA Ophthalmol 2014) [46]. Some observational data suggest vitamin E may help slow lens opacification, but supplementation trials have not confirmed this [47][48].

Liver Disease (NAFLD/MASLD)

High-dose natural alpha-tocopherol has the strongest evidence base in liver disease, making it one of the few conditions where therapeutic vitamin E supplementation is recommended by medical societies.

NASH — positive (natural form): In 2022, the American Heart Association advised that daily supplementation with 800 IU of alpha-tocopherol "can be considered for some patients with biopsy-proven NASH who are not diabetic and have not yet progressed to cirrhosis" (Duell, Arterioscler Thromb Vasc Biol 2022) [49]. This recommendation was based on two key studies:

• A study of 80 non-diabetic adults (average age 60) with NAFLD found that 800 IU/day of natural vitamin E (d-alpha-tocopherol) for 22 months modestly reduced liver fat buildup, decreased liver inflammation, and lowered liver enzymes (ALT and AST), although it did not reduce fibrosis compared to placebo (Sanyal, N Engl J Med 2010) [50].
• A study of 173 children and adolescents (average age 13) with NAFLD found that 800 IU/day of natural vitamin E for 22 months decreased hepatocellular ballooning and resolved liver damage in 58% of those taking vitamin E compared to 28% on placebo (Lavine, JAMA 2011) [51].

Synthetic form — no benefit: A study of 203 adults (average age 51) with MASLD found that 1,000 mg of synthetic vitamin E (dl-alpha-tocopheryl acetate), alone or with DHA, for 6 months did not significantly reduce liver fat or improve liver enzymes compared to placebo (Alkhouri, Aliment Pharmacol Ther 2024) [52]. This highlights the importance of form: natural alpha-tocopherol appears effective where synthetic does not.

Tocotrienols — insufficient evidence: A study suggested that delta-tocotrienol (300 mg twice daily) may have effects similar to alpha-tocopherol on the liver (Pervaz, Complement Ther Med 2022) [53]. However, an open-label study of 32 adults with type 2 diabetes and NAFLD found that 200 mg of tocotrienol twice daily for 3 months did not significantly reduce liver enzymes or liver stiffness (Devarajan, J Indian Med Assoc 2023) [54]. More research is needed.

Important caveat: The AHA cautioned that vitamin E treatment for NASH may not be appropriate for men with or at high risk for prostate cancer, and that there is some evidence vitamin E supplementation may increase the risk of heart failure [49].

Parkinson's Disease

An uncontrolled pilot study in people with early-stage Parkinson's disease suggested that 3,200 IU of vitamin E combined with 3,000 mg of vitamin C daily may delay the need for levodopa by approximately 2.5-3 years (Fahn, Ann N Y Acad Sci 1989) [55]. However, the definitive multicenter RCT (DATATOP) among 800 people with early-stage Parkinson's disease found that 2,000 IU/day of alpha-tocopherol for an average of 14 months did not delay the onset of disability or the need for levodopa compared to placebo (Parkinson Study Group, N Engl J Med 1993) [56].

Diabetes and Diabetic Neuropathy

Diabetic neuropathy — mixed results by age: Taking 400 mg/day of vitamin E in addition to diabetic medications (glibenclamide and metformin) decreased pain in people with diabetic neuropathy, but only in those aged 50 or older; there was no significant effect in younger individuals (Rajanandh, Pharmacol Rep 2014) [57].

Tocotrienols for neuropathy — no benefit: Taking 400 mg of mixed tocotrienols twice daily for 12 months did not reduce pain compared to placebo in patients with diabetic neuropathy (Hor, JAMA Neurol 2018) [58].

Cyclic Mastalgia (Breast Pain)

Combination therapy — modest benefit: Among 126 premenopausal women with cyclic mastalgia, vitamin E 400 mg plus evening primrose oil 1,000 mg twice daily for 6 months slightly reduced worst pain by 4.0 points and average pain by 3.7 points (on a 0-45 scale) compared to baseline — statistically significant versus placebo, though placebo showed 2.6-point reductions. Neither vitamin E alone nor evening primrose oil alone was as effective as the combination (Kumari, Cureus 2024) [59].

Higher-dose trial — no benefit: A US study of 31 women found that vitamin E 400 IU or evening primrose oil 1,000 mg (alone or together) three times daily for 6 months did not significantly reduce breast pain compared to placebo (Pruthi, Altern Med Rev 2010) [60].

Achilles Tendinopathy

Prophylactic use of vitamin E with selenium may slightly reduce the severity (but not incidence) of Achilles tendinopathy caused by fluoroquinolone antibiotics. A small study found that 400 IU vitamin E plus 200 mcg selenium daily — started with levofloxacin treatment and continued 4 weeks — reduced Achilles tendon pain by 1.6 points (on a 0-10 scale) at 3 months post-treatment. However, there was no significant difference in tendinopathy incidence, and the study lacked a placebo control (Misca, Pharmaceuticals 2025) [61].

Topical Uses

Sunburn prevention: Topical creams or gels containing vitamin E in combination with melatonin or vitamin C have shown slight promise for preventing sunburn (Dreher, Br J Dermatol 1998) [62], but the effect is far less than standard sunscreen. Oral vitamin E supplementation (400 IU/day) does not appear to protect against UV-induced skin damage (Werninghaus, Arch Dermatol 1994) [63].

Wrinkle reduction: Several studies report modest wrinkle reduction with topical formulas combining vitamin E with other ingredients such as vitamin C, ceramides, retinol, squalene, glycerin, and niacinamide [64][65][66]. However, there is no clinical evidence that topical vitamin E alone reduces wrinkles. Stability is a concern — cosmeceuticals containing vitamin E may lose effectiveness after the product is opened and exposed to air and light [67]. The synthetic dl-alpha-tocopheryl acetate form is the most stable for topical use.

Scarring: Vitamin E cream does not appear to help prevent, and may in some cases worsen, surgical scarring (Baumann, Dermatol Surg 1999) [68].

Hair Growth (Tocotrienols)

A study in 35 adults with hair loss found that 50 mg of mixed tocotrienols daily for 8 months increased hair count in a target area by approximately 35% compared to a 0.1% decrease with placebo. Hair weight did not change significantly in either group (Beoy, Trop Life Sci Res 2010) [13].

Recommended Dosing

Recommended Dietary Allowances (RDAs)

The RDA is based on milligrams of active alpha-tocopherol (d-alpha-tocopherol) [1][2].

Age Group	RDA (mg/day)	Natural (IU)	Synthetic (IU)
0-6 months*	4 mg	6 IU	9 IU
7-12 months*	5 mg	7 IU	11 IU
1-3 years	6 mg	9 IU	13 IU
4-8 years	7 mg	10 IU	16 IU
9-13 years	11 mg	16 IU	24 IU
14+ years	15 mg	22 IU	33 IU
Lactating women	19 mg	28 IU	42 IU

*Adequate Intake (AI), not RDA, for infants.

Tolerable Upper Intake Levels (ULs)

ULs apply to alpha-tocopherol from supplements and fortified foods, not from food sources [1][2]. Because both active and inactive stereoisomers in synthetic vitamin E may contribute to bleeding risk, ULs for synthetic vitamin E are lower than for natural [5].

Age Group	UL (mg/day)	Natural (IU)	Synthetic (IU)
1-3 years	200 mg	300 IU	220 IU
4-8 years	300 mg	450 IU	330 IU
9-13 years	600 mg	900 IU	660 IU
14-18 years	800 mg	1,200 IU	880 IU
19+ years	1,000 mg	1,500 IU	1,100 IU

Dosing for Specific Conditions

When vitamin E is used at doses higher than nutritional requirements to treat or prevent medical conditions, study doses have ranged from 100 IU to 2,000 IU daily [5]:

• NASH/NAFLD (non-diabetic, without cirrhosis): 800 IU/day natural alpha-tocopherol (d-alpha-tocopherol), per AHA recommendation [49][50][51].
• Alzheimer's disease: 2,000 IU/day (dl-alpha-tocopherol, given as 1,000 IU twice daily) has shown modest benefit for functional decline in established Alzheimer's. This far exceeds the UL and requires physician supervision [14][15].
• General antioxidant support: Most clinical trials used 100-600 IU/day, though results have been inconsistent [5].
• Rheumatoid arthritis: 600 IU twice daily (1,200 IU/day) has shown some promise in preliminary research [5].

Note: Dosages above the UL are potentially dangerous and should only be used under medical supervision. A meta-analysis found a slight increase in mortality risk among older individuals with existing medical conditions using more than 400 IU/day (Miller, Ann Intern Med 2005) [69].

Why MicroVitamin Excludes Vitamin E

Dr Brad Stanfield's MicroVitamin deliberately excludes vitamin E based on the weight of clinical trial evidence. The SELECT trial demonstrated a 17% increased risk of prostate cancer at 400 IU/day of synthetic vitamin E [7]. The US Preventive Services Task Force found no net benefit for cardiovascular disease or cancer prevention [8]. Unlike water-soluble vitamins that are excreted when consumed in excess, fat-soluble vitamins like vitamin E accumulate in the body, and supplementing on top of dietary intake can push levels into a range associated with harm. Most people in the US obtain adequate vitamin E from dietary sources, and the RDA of 15 mg/day is easily met through nuts, seeds, and vegetable oils.

Safety and Side Effects

Bleeding Risk

The primary safety concern with vitamin E supplementation is an increased risk of hemorrhage. Vitamin E inhibits platelet aggregation and antagonizes vitamin K-dependent clotting factors [1][2]. This risk is clinically relevant at doses above 400 IU/day and is the basis for the UL.

A review of clinical studies found vitamin E may reduce ischemic stroke risk by 10% but increase hemorrhagic stroke risk by 22% (Schurks, BMJ 2010) [28]. The Physicians' Health Study II confirmed an increased risk of hemorrhagic stroke with 400 IU synthetic vitamin E every other day (Sesso, JAMA 2008) [27]. The ATBC study in Finnish male smokers also found increased hemorrhagic stroke incidence with 50 mg/day vitamin E for 6 years [32].

Prostate Cancer Risk

The SELECT trial provides the strongest evidence: 400 IU/day of synthetic vitamin E increased prostate cancer risk by 17% in healthy men aged 50 and older (Klein, JAMA 2011) [7]. Further analysis showed the risk was modified by selenium status — men low in selenium who took vitamin E had 46% increased risk of low-grade and 111% increased risk of high-grade prostate cancer (Kristal, JNCI 2014) [31]. This finding led the American Heart Association to caution that vitamin E treatment for NASH may not be appropriate for men at high risk for prostate cancer [49].

All-Cause Mortality

Two meta-analyses raised concerns about vitamin E and mortality. A meta-analysis found increased risk of death at doses above 400 IU/day, with risk beginning to increase at 150 IU/day (Miller, Ann Intern Med 2005) [69]. A separate meta-analysis of antioxidant supplement trials found that vitamin E, taken singly (mean 569 IU/day) or combined with other antioxidants, significantly increased mortality risk (Bjelakovic, JAMA 2007) [70].

However, participants in these studies were typically middle-aged or older with chronic diseases. A review of studies in healthy individuals found no convincing evidence that vitamin E increased mortality for primary prevention [2][71]. The implications remain debated.

Heart Failure

The HOPE-TOO trial found that participants taking vitamin E were 13% more likely to experience and 21% more likely to be hospitalized for heart failure — a statistically significant but unexpected finding (Lonn, JAMA 2005) [24]. This has not been consistently replicated in other large studies.

Antioxidant Interference with Cancer Treatment

Oncologists generally advise against antioxidant supplements, including vitamin E, during chemotherapy or radiotherapy because they may reduce treatment effectiveness by protecting cancerous cells from oxidative damage [72][73]. Although a systematic review of RCTs has questioned this concern [74], vitamin E should be avoided during active cancer treatment unless specifically approved by the treating oncologist.

Special Populations

• Premature infants: Very low birth weight infants (<1,500 g) may be vitamin E deficient. Supplementation may reduce some complications but can increase infection risk [1][2].
• People on low-fat diets: May get insufficient vitamin E unless they carefully select foods rich in nuts, seeds, fruits, and vegetables [5][6].
• Rare inherited disorders: Those with abetalipoproteinemia require 5-10 g/day; those with AVED require large doses to prevent progressive nerve damage [1][2].

Drug Interactions

Vitamin E supplements interact with several medication classes. People taking these medications should discuss vitamin E use with their healthcare provider [1][2].

Anticoagulant and Antiplatelet Medications

Vitamin E inhibits platelet aggregation and antagonizes vitamin K-dependent clotting factors. Taking large doses with warfarin (Coumadin), heparin, aspirin, or other blood thinners increases bleeding risk, especially in conjunction with low vitamin K intake. Clinically significant effects probably require doses above 400 IU/day [1][2].

Simvastatin and Niacin

A combination of antioxidants including vitamin E and vitamin C blunted the HDL-raising benefits of simvastatin-niacin therapy, reducing levels of HDL2 (the most cardioprotective component) in patients with coronary artery disease (Brown, N Engl J Med 2001; Cheung, Arterioscler Thromb Vasc Biol 2001) [29][30].

Chemotherapy and Radiation Therapy

Vitamin E and other antioxidants may reduce the efficacy of chemotherapy and radiotherapy by inhibiting the oxidative damage these treatments rely on to kill cancer cells. Oncologists generally advise against antioxidant supplementation during cancer treatment [72][73].

Cholesterol-Lowering Agents

Some evidence suggests vitamin E supplementation may reduce the effectiveness of lipid-lowering therapies beyond the simvastatin-niacin interaction described above [29][30]. Patients on statin therapy should discuss vitamin E use with their prescriber.

Dietary Sources

Vitamin E is widely available in the food supply. Nuts, seeds, and vegetable oils are the richest sources of alpha-tocopherol. The RDA of 15 mg/day is achievable through diet for most people making informed food choices [1][2].

Selected Food Sources of Alpha-Tocopherol

Food	Serving Size	Alpha-Tocopherol (mg)	% DV (15 mg)
Wheat germ oil	1 tablespoon	20.3	135%
Sunflower seeds, dry roasted	1 ounce	7.4	49%
Almonds, dry roasted	1 ounce	6.8	45%
Sunflower oil	1 tablespoon	5.6	37%
Safflower oil	1 tablespoon	4.6	31%
Hazelnuts, dry roasted	1 ounce	4.3	29%
Peanut butter	2 tablespoons	2.9	19%
Peanuts, dry roasted	1 ounce	2.2	15%
Corn oil	1 tablespoon	1.9	13%
Spinach, boiled	1/2 cup	1.9	13%
Broccoli, chopped, boiled	1/2 cup	1.2	8%
Soybean oil	1 tablespoon	1.1	7%
Kiwifruit	1 medium	1.1	7%
Mango, sliced	1/2 cup	0.7	5%
Tomato, raw	1 medium	0.7	5%

Source: NIH ODS, USDA FoodData Central [1][75].

Practical Notes

• Most vitamin E in the American diet comes as gamma-tocopherol from soybean, canola, corn, and other vegetable oils — not alpha-tocopherol [2][4].
• A single ounce of sunflower seeds or almonds provides roughly half the daily requirement.
• People on very low-fat diets may need to increase their intake of nuts, seeds, fruits, and vegetables to meet requirements (Gao, J Nutr 2006) [6].
• Serious dietary deficiency is rare in the US and typically occurs only with underlying malabsorption conditions [1][2].

References

1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes: Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC: National Academy Press, 2000.

2. National Institutes of Health, Office of Dietary Supplements. "Vitamin E — Health Professional Fact Sheet." Updated March 26, 2021. https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/

3. Traber MG. "Vitamin E regulatory mechanisms." Annu Rev Nutr. 2007;27:347-62. https://pubmed.ncbi.nlm.nih.gov/17439363/

4. Dietrich M, Traber MG, Jacques PF, et al. "Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer?" Am J Coll Nutr. 2006;25:292-9. https://pubmed.ncbi.nlm.nih.gov/16943450/

5. ConsumerLab. "Vitamin E Supplements Review." https://www.consumerlab.com/reviews/vitamin-e-supplements-cream-oil-tocopherol/vitamine/

6. Gao X, Wilde PE, Lichtenstein AH, et al. "The maximal amount of dietary alpha-tocopherol intake in U.S. adults (NHANES 2001-2002)." J Nutr. 2006;136:1021-6. https://pubmed.ncbi.nlm.nih.gov/16549467/

7. Klein EA, Thompson IM Jr, Tangen CM, et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA. 2011;306:1549-1556. https://pubmed.ncbi.nlm.nih.gov/21990298/

8. US Preventive Services Task Force. "Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer." JAMA. 2022. https://doi.org/10.1001/jama.2021.15650

9. US Food and Drug Administration. "Food Labeling: Revision of the Nutrition and Supplement Facts Labels." 2016.

10. Yang CS, Suh N, Kong AN. "Does vitamin E prevent or promote cancer?" Cancer Prev Res. 2012;5(5):701-5.

11. Tucker LA. "Alpha- and Gamma-Tocopherol and Telomere Length in 5768 US Men and Women: A NHANES Study." Nutrients. 2017;9(6):601. https://doi.org/10.3390/nu9060601

12. Mensink RP, et al. "A vitamin E concentrate rich in tocotrienols had no effect on serum lipids." Am J Clin Nutr. 1999;69:213-9.

13. Beoy LA, Woei WJ, Hay YK. "Effects of tocotrienol supplementation on hair growth in human volunteers." Trop Life Sci Res. 2010;21(2):91-9.

14. Dysken MW, Sano M, Asthana S, et al. "Effect of vitamin E and memantine on functional decline in Alzheimer disease." JAMA. 2014;311(1):33-44. https://pubmed.ncbi.nlm.nih.gov/24381967/

15. Sano M, Ernesto C, Thomas RG, et al. "A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease." N Engl J Med. 1997;336:1216-22. https://pubmed.ncbi.nlm.nih.gov/9110909/

16. Petersen RC, Thomas RG, Grundman M, et al. "Vitamin E and donepezil for the treatment of mild cognitive impairment." N Engl J Med. 2005;352:2379-88. https://pubmed.ncbi.nlm.nih.gov/15829527/

17. Kryscio RJ, Abner EL, Caban-Holt A, et al. "Association of Antioxidant Supplement Use and Dementia (PREADViSE)." JAMA Neurol. 2017;74(5):567-573.

18. Kang JH, Cook N, Manson J, et al. "A randomized trial of vitamin E supplementation and cognitive function in women." Arch Intern Med. 2006;166:2462-8. https://pubmed.ncbi.nlm.nih.gov/17159011/

19. Morris MC, Evans DA, Bienias JL, et al. "Vitamin E and cognitive decline in older persons." Arch Neurol. 2002;59:1125-32. https://pubmed.ncbi.nlm.nih.gov/12117360/

20. Isaac MGEKN, Quinn R, Tabet N. "Vitamin E for Alzheimer's disease and mild cognitive impairment." Cochrane Database Syst Rev. 2008;(3):CD002854. https://pubmed.ncbi.nlm.nih.gov/18646084/

21. Stampfer MJ, et al. "Vitamin E consumption and the risk of coronary disease in women." N Engl J Med. 1993;328:1444-9. https://pubmed.ncbi.nlm.nih.gov/8479463/

22. Knekt P, et al. "Antioxidant vitamin intake and coronary mortality in a longitudinal population study." Am J Epidemiol. 1994;139:1180-9. https://pubmed.ncbi.nlm.nih.gov/8209876/

23. Yusuf S, et al. "Vitamin E supplementation and cardiovascular events in high-risk patients." N Engl J Med. 2000;342:154-60. https://pubmed.ncbi.nlm.nih.gov/10639540/

24. Lonn E, et al. "Effects of long-term vitamin E supplementation on cardiovascular events and cancer." JAMA. 2005;293:1338-47. https://pubmed.ncbi.nlm.nih.gov/15769967/

25. Waters DD, et al. "Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis." JAMA. 2002;288:2432-40. https://pubmed.ncbi.nlm.nih.gov/12435256/

26. Lee IM, et al. "Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study." JAMA. 2005;294:56-65. https://pubmed.ncbi.nlm.nih.gov/15998891/

27. Sesso HD, et al. "Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II." JAMA. 2008;300:2123-33. https://pubmed.ncbi.nlm.nih.gov/18997197/

28. Schurks M, et al. "Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials." BMJ. 2010;341:c5702.

29. Brown BG, et al. "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." N Engl J Med. 2001;345:1583-92. https://pubmed.ncbi.nlm.nih.gov/11757504/

30. Cheung MC, et al. "Antioxidant supplements block the response of HDL to simvastatin-niacin therapy." Arterioscler Thromb Vasc Biol. 2001;21:1320-6. https://pubmed.ncbi.nlm.nih.gov/11498460/

31. Kristal AR, et al. "Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk." J Natl Cancer Inst. 2014;106(3):djt456. https://pubmed.ncbi.nlm.nih.gov/24872528/

32. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers." N Engl J Med. 1994;330:1029-35. https://pubmed.ncbi.nlm.nih.gov/8127329/

33. Heinonen OP, et al. "Prostate cancer and supplementation with alpha-tocopherol and beta-carotene." J Natl Cancer Inst. 1998;90(6):440-6. https://pubmed.ncbi.nlm.nih.gov/9521168/

34. Bostick RM, et al. "Reduced risk of colon cancer with high intakes of vitamin E: the Iowa Women's Health Study." Cancer Res. 1993;15:4230-7. https://pubmed.ncbi.nlm.nih.gov/8364919/

35. Wu K, et al. "A prospective study on supplemental vitamin E intake and risk of colon cancer." Cancer Epidemiol Biomarkers Prev. 2002;11:1298-304. https://pubmed.ncbi.nlm.nih.gov/12433706/

36. Jacobs EJ, et al. "Vitamin C and vitamin E supplement use and bladder cancer mortality." Am J Epidemiol. 2002;156:1002-10. https://pubmed.ncbi.nlm.nih.gov/12446256/

37. Zhang W, et al. "Vitamin E intake and risk of liver cancer in a large cohort study." J Natl Cancer Inst. 2012;104(15):1173-81.

38. Huang H, et al. "Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis." Contemp Oncol (Pozn). 2016;20(3):237-241.

39. Loprinzi CL, et al. "Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy: ASCO Guideline Update." J Clin Oncol. 2020;38(28):3325-3348.

40. Chong EWT, et al. "Dietary antioxidants and primary prevention of age-related macular degeneration." BMJ. 2007;335:755. https://pubmed.ncbi.nlm.nih.gov/17923721/

41. Taylor HR, et al. "Vitamin E supplementation and macular degeneration." BMJ. 2002;325:11. https://pubmed.ncbi.nlm.nih.gov/12098721/

42. Teikari JM, et al. "Long-term supplementation with alpha-tocopherol and beta-carotene and age-related cataract." Acta Ophthalmol Scand. 1997;75:634-40. https://pubmed.ncbi.nlm.nih.gov/9527321/

43. Age-Related Eye Disease Study Research Group. "AREDS report no. 8." Arch Ophthalmol. 2001;119:1417-36. https://pubmed.ncbi.nlm.nih.gov/11594942/

44. AREDS2 Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration." JAMA. 2013;309:2005-15. https://pubmed.ncbi.nlm.nih.gov/23644932/

45. Christen WG, et al. "Age-related cataract in a randomized trial of vitamins E and C in men." Arch Ophthalmol. 2010;128(11):1397-405.

46. Christen WG, et al. "Age-related cataract in men in the SELECT eye endpoints study." JAMA Ophthalmol. 2014;132(3):317-23.

47. Leske MC, et al. "Antioxidant vitamins and nuclear opacities." Ophthalmology. 1998;105:831-6. https://pubmed.ncbi.nlm.nih.gov/9593383/

48. Jacques PF, et al. "Long-term nutrient intake and 5-year change in nuclear lens opacities." Arch Ophthalmol. 2005;123:517-26. https://pubmed.ncbi.nlm.nih.gov/15824226/

49. Duell PB, et al. "Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: AHA Scientific Statement." Arterioscler Thromb Vasc Biol. 2022;42:e168-e185.

50. Sanyal AJ, et al. "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis." N Engl J Med. 2010;362:1675-85.

51. Lavine JE, et al. "Effect of vitamin E or metformin for treatment of NAFLD in children: the TONIC trial." JAMA. 2011;305:1659-68.

52. Alkhouri N, et al. "Effect of vitamin E and DHA on MASLD." Aliment Pharmacol Ther. 2024.

53. Pervaz M, et al. "Delta-tocotrienol in NAFLD." Complement Ther Med. 2022.

54. Devarajan A, et al. "Tocotrienol in type 2 diabetes and NAFLD." J Indian Med Assoc. 2023.

55. Fahn S. "An open trial of high-dosage antioxidants in early Parkinson's disease." Ann N Y Acad Sci. 1989;570:186-96.

56. Parkinson Study Group. "Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease." N Engl J Med. 1993;328:176-83.

57. Rajanandh MG, et al. "Assessment of antioxidant supplementation on neuropathic pain in diabetic neuropathy." Pharmacol Rep. 2014;66(1):44-8.

58. Hor CP, et al. "Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy." JAMA Neurol. 2018;75(4):444-452.

59. Kumari A, et al. "Vitamin E and evening primrose oil for cyclic mastalgia." Cureus. 2024.

60. Pruthi S, et al. "Vitamin E and evening primrose oil for cyclical mastalgia: a randomized pilot study." Altern Med Rev. 2010;15(1):59-67.

61. Misca C, et al. "Prophylactic vitamin E and selenium for fluoroquinolone-induced Achilles tendinopathy." Pharmaceuticals. 2025.

62. Dreher F, et al. "Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema." Br J Dermatol. 1998;139(2):332-9.

63. Werninghaus K, et al. "Evaluation of the photoprotective effect of oral vitamin E supplementation." Arch Dermatol. 1994;130(10):1257-61.

64. Mitsuishi T, et al. "Topical phytonadione, retinol and vitamins C and E on wrinkles." J Cosmet Dermatol. 2004;3(2):73-5.

65. Boen M, et al. "The Role of Topical Vitamins and Cosmeceuticals." J Clin Aesthet Dermatol. 2020;13(9):28-36.

66. Takuathung MN, et al. "Topical anti-wrinkle formulations." J Clin Med. 2023.

67. Keen MA, Hassan I. "Vitamin E in dermatology." Indian Dermatol Online J. 2016;7(4):311-315.

68. Baumann LS, Spencer J. "The effects of topical vitamin E on the cosmetic appearance of scars." Dermatol Surg. 1999;25(4):311-5.

69. Miller ER 3rd, et al. "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality." Ann Intern Med. 2005;142:37-46. https://pubmed.ncbi.nlm.nih.gov/15537682/

70. Bjelakovic G, et al. "Mortality in randomized trials of antioxidant supplements." JAMA. 2007;297:842-57. https://pubmed.ncbi.nlm.nih.gov/17327526/

71. Hathcock JN, et al. "Vitamins E and C are safe across a broad range of intakes." Am J Clin Nutr. 2005;81:367-45. https://pubmed.ncbi.nlm.nih.gov/15699220/

72. Doyle C, et al. "Nutrition and physical activity during and after cancer treatment: ACS guide." CA Cancer J Clin. 2006;56:323-53. https://pubmed.ncbi.nlm.nih.gov/17135691/

73. Lawenda BD, et al. "Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?" J Natl Cancer Inst. 2008;100:773-83. https://pubmed.ncbi.nlm.nih.gov/18505970/

74. Block KI, et al. "Impact of antioxidant supplementation on chemotherapeutic efficacy." Cancer Treat Rev. 2007;33:407-18. https://pubmed.ncbi.nlm.nih.gov/17367936/

75. U.S. Department of Agriculture, FoodData Central. https://fdc.nal.usda.gov/